Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Fig. 3

Kaplan–Meier curves for overall survival and progression-free survival. a The median overall survival for the second-line and late-line groups were 10.3 (95% CI 4.4–NA) and 10.4 (95% CI 3.7–14.6) months (P = 0.986), respectively. b The median progression-free survival for the second-line and late-line groups were 2.7 (95% CI 0.9–NA) and 2.7 (95% CI 1.6–7.3) months (P = 0.808), respectively, according to RECIST. (c) The median progression-free survival of the second-line and late-line groups were 1.8 (95% CI 0.9–NA) and 3.5 (95% CI 1.6–7.3) months (P = 0.398), respectively, according to mRECIST

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us